ZA201008786B - Oxazolopyrimidines as edg-1 receptor agonists - Google Patents

Oxazolopyrimidines as edg-1 receptor agonists

Info

Publication number
ZA201008786B
ZA201008786B ZA2010/08786A ZA201008786A ZA201008786B ZA 201008786 B ZA201008786 B ZA 201008786B ZA 2010/08786 A ZA2010/08786 A ZA 2010/08786A ZA 201008786 A ZA201008786 A ZA 201008786A ZA 201008786 B ZA201008786 B ZA 201008786B
Authority
ZA
South Africa
Prior art keywords
oxazolopyrimidines
edg
receptor agonists
agonists
receptor
Prior art date
Application number
ZA2010/08786A
Other languages
English (en)
Inventor
Dieter Kadereit
Matthias Schaefer
Werngard Czechtizky
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ZA201008786B publication Critical patent/ZA201008786B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2010/08786A 2008-07-15 2010-12-07 Oxazolopyrimidines as edg-1 receptor agonists ZA201008786B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290694 2008-07-15
PCT/EP2009/004770 WO2010006704A1 (en) 2008-07-15 2009-07-02 Oxazolopyrimidines as edg-1 receptor agonists

Publications (1)

Publication Number Publication Date
ZA201008786B true ZA201008786B (en) 2012-01-25

Family

ID=39967817

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/08786A ZA201008786B (en) 2008-07-15 2010-12-07 Oxazolopyrimidines as edg-1 receptor agonists

Country Status (20)

Country Link
US (1) US8735387B2 (https=)
EP (2) EP2318415B1 (https=)
JP (1) JP5449346B2 (https=)
KR (1) KR20110042286A (https=)
CN (1) CN102159582B (https=)
AR (1) AR072496A1 (https=)
AU (1) AU2009270511B2 (https=)
BR (1) BRPI0915781A2 (https=)
CA (1) CA2730843A1 (https=)
CL (1) CL2011000071A1 (https=)
CO (1) CO6331436A2 (https=)
IL (1) IL210639A0 (https=)
MA (1) MA32455B1 (https=)
MX (1) MX2011000211A (https=)
NZ (1) NZ590377A (https=)
RU (1) RU2503680C2 (https=)
TW (1) TW201016707A (https=)
UY (1) UY31981A (https=)
WO (1) WO2010006704A1 (https=)
ZA (1) ZA201008786B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079981A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de acido carboxilico que comprenden un anillo de oxoazolopirimidina 2,5,7- sustituido
AR079980A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
CN102791717B (zh) * 2010-01-14 2016-03-30 赛诺菲 具有2,5-取代的噁唑并嘧啶环的羧酸衍生物
DK2523960T3 (da) * 2010-01-14 2014-01-20 Sanofi Sa Heterocykliske carboxylsyrederivater med en 2,5-substitueret oxazolopyrimidinring
CN102834400B (zh) * 2010-01-14 2015-06-10 赛诺菲 2,5-取代的*唑并嘧啶衍生物
BR122017023123B1 (pt) 2010-03-12 2018-04-24 Nippon Soda Co., Ltd. Método para produzir derivado de picolina halogenada
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
US8907093B2 (en) 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
WO2013163244A1 (en) * 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
LT2841437T (lt) 2012-04-26 2017-09-11 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
US10577308B2 (en) 2015-03-26 2020-03-03 The Florey Institute Sodium channel modulators
CN117529325A (zh) * 2021-04-21 2024-02-06 纳特科药品有限公司 制备7-(吗啉基)-2-(N-哌嗪基)甲基噻吩并[2,3-c]吡啶衍生物的改进方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679682A (en) * 1970-04-23 1972-07-25 Fmc Corp CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES
CN100378107C (zh) * 2001-05-14 2008-04-02 诺瓦提斯公司 唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
MXPA05010802A (es) 2003-04-25 2005-12-14 Univ Cardiff Compuestos heterociclicos para el uso en el tratamiento de infecciones virales.
CA2523677A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
BRPI0410439A (pt) * 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
MXPA06002618A (es) 2003-09-09 2006-06-05 Ono Pharmaceutical Co Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2005067546A2 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
EP1965807A4 (en) * 2005-11-23 2010-10-27 Epix Delaware Inc S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE
EP1900729A1 (en) * 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors

Also Published As

Publication number Publication date
CN102159582B (zh) 2014-05-07
CL2011000071A1 (es) 2011-05-06
EP2583720A1 (en) 2013-04-24
NZ590377A (en) 2011-11-25
WO2010006704A1 (en) 2010-01-21
US8735387B2 (en) 2014-05-27
AU2009270511A1 (en) 2010-01-21
RU2503680C2 (ru) 2014-01-10
JP2011527994A (ja) 2011-11-10
EP2318415A1 (en) 2011-05-11
TW201016707A (en) 2010-05-01
AU2009270511B2 (en) 2013-07-18
EP2318415B1 (en) 2013-02-20
RU2011105388A (ru) 2012-08-20
US20110190490A1 (en) 2011-08-04
MA32455B1 (fr) 2011-07-03
BRPI0915781A2 (pt) 2015-11-10
CO6331436A2 (es) 2011-10-20
CN102159582A (zh) 2011-08-17
UY31981A (es) 2010-02-26
CA2730843A1 (en) 2010-01-21
IL210639A0 (en) 2011-03-31
AR072496A1 (es) 2010-09-01
KR20110042286A (ko) 2011-04-26
JP5449346B2 (ja) 2014-03-19
MX2011000211A (es) 2011-03-03

Similar Documents

Publication Publication Date Title
IL210639A0 (en) Oxazolopyrimidines as edg-1 receptor agonists
TWI367207B (en) Substituted pyrrolidine-2-carboxamides
IL208919A0 (en) Gpr119 receptor agonists
EP2345636A4 (en) AGONIST OF THE CASR
GB0810902D0 (en) New compounds
ZA201103154B (en) Melanocortin receptor agonists
IL212551A0 (en) Cxcr4 receptor compounds
IL218649A0 (en) Oxytocin receptor agonists
GB2463377B (en) Dual mount adapter
ZA201200641B (en) Sphingosine-1-phosphate receptor agonists
IL210344A0 (en) New compounds
GB0708226D0 (en) Y-receptor agonists
AU322206S (en) Monitor
IL208281A0 (en) Substituted cyclohexyldiamines
IL209175A0 (en) Substituted qunazolines
GB2471975B (en) Tripod-connecting adapter
GB0817513D0 (en) Co-crystals
GB0823445D0 (en) Biomarker
GB0817976D0 (en) Co-crystals
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
HU0800478D0 (en) New compounds
PL2328593T3 (pl) Kardioplegiczny preparat
HK1168105A (en) Sphingosine-1-phosphate receptor agonists
AU4585P (en) WES05 Westringia fruticosa
AU2008903337A0 (en) TPOR Receptor Agonists